Networking Pharma Pharmaceutical manufacturing 
Impetus Digital
AUGUST 2, 2024
Manufacturing Optimization While the manufacturing industry lags behind others in terms of AI uptake, there is no shortage of potential ways to leverage this technology. Supply Chain Management Due to geopolitical and climate-related challenges , Pharma supply chain disruptions are becoming increasingly common and complex.
pharmaphorum
OCTOBER 26, 2022
When people think about pharma, they often think about “big” pharma: large, faceless corporations. The status isn’t awarded lightly and Chiesi is the largest pharmaceutical manufacturer to be named a B Corp. “We The post How one pharma “family business” places patients first appeared first on.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JULY 25, 2022
Consequently, pharmaceutical manufacturers risk their reputation if impersonating products fail to deliver the expected quality or health impact. In fact, the most recent estimate from the World Customs Organization places the global fake pharma market at $200 billion. But what exactly does this look like? .
European Pharmaceutical Review
SEPTEMBER 28, 2023
When questioned about which technologies he considered have potential to advance the sector, Chornet emphasised that not only is mRNA as a vaccine technology “a very promising and interesting platform [but that it is] disruptive and a game changer technology for vaccine [manufacturing] and overall biotech.”
Pharma Marketing Network
JANUARY 18, 2023
Bob is a life sciences and technology marketing leader with more than 25 years of experience working directly for pharmaceutical manufacturers (Merck, AstraZeneca, and Shire) and for technology companies that serve the industry (Appature, IQVIA, and Sparta). The post Bob Harrell appeared first on Pharma Marketing Network.
PM360
SEPTEMBER 30, 2024
Sustainable Tech’s Positive Effect on Pharma Funding Recent innovations, including rapid advancements in AI-powered technologies and GLP-1s, have significantly impacted the investment climate and consolidated funding to a smaller number of organizations in the last eight months.
pharmaphorum
DECEMBER 16, 2022
Of significant interest to the pharma industry are the suggestions in the draft text that money granted for research on infectious diseases could include specifications on how eventual products could be marketed.
Expert insights. Personalized for you.
92 
Let's personalize your content